# The Prognosis of Lipid Reprogramming With Rosuvastatin, in Castrated Egyptian Prostate Cancer Patients

> **NCT04776889** · PHASE4 · COMPLETED · sponsor: **National Cancer Institute, Egypt** · enrollment: 70 (actual)

## Conditions studied

- Prostate Cancer Metastatic

## Interventions

- **DRUG:** Rosuvastatin 20mg
- **PROCEDURE:** surgical castration

## Key facts

- **NCT ID:** NCT04776889
- **Lead sponsor:** National Cancer Institute, Egypt
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-15
- **Primary completion:** 2020-12-30
- **Final completion:** 2020-12-30
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2021-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04776889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04776889, "The Prognosis of Lipid Reprogramming With Rosuvastatin, in Castrated Egyptian Prostate Cancer Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04776889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*